Wall Street Zen Downgrades BlossomHill Therapeutics (NASDAQ:BLSM) to Sell

by · The Markets Daily

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms have also issued reports on BLSM. Lifesci Capital started coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective on the stock. Guggenheim boosted their target price on BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of BlossomHill Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. initiated coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price target for the company. Finally, Leerink Partners raised their price target on BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, September 21st. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

Get Our Latest Analysis on BlossomHill Therapeutics

BlossomHill Therapeutics Price Performance

Shares of BLSM opened at $19.69 on Friday. The company has a 50-day moving average price of $19.89. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last issued its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). On average, research analysts forecast that BlossomHill Therapeutics will post -5.54 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Orbimed Advisors Llc bought 625,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Vincent Liptak bought 2,200 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $35,200.00. Following the transaction, the general counsel directly owned 111,412 shares of the company’s stock, valued at $1,782,592. The trade was a 2.01% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

Further Reading